Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Gregory M. Weinhoff Sells 10,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total transaction of $163,400.00. Following the transaction, the insider now directly owns 134,021 shares in the company, valued at $2,189,903.14. The trade was a 6.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Centessa Pharmaceuticals Stock Performance

NASDAQ CNTA traded down $1.27 during trading hours on Wednesday, hitting $14.54. The company had a trading volume of 2,499,419 shares, compared to its average volume of 537,096. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.92 billion, a P/E ratio of -9.50 and a beta of 1.54. Centessa Pharmaceuticals plc has a fifty-two week low of $7.75 and a fifty-two week high of $19.09. The business has a fifty day simple moving average of $16.51 and a 200-day simple moving average of $16.43.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.04. Equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on CNTA shares. Guggenheim reaffirmed a “buy” rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday. TD Cowen initiated coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating on the stock. Finally, Morgan Stanley reiterated an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $26.00.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at approximately $31,000. GAMMA Investing LLC grew its stake in shares of Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after purchasing an additional 865 shares in the last quarter. Barclays PLC increased its holdings in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after purchasing an additional 4,952 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at about $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Centessa Pharmaceuticals in the fourth quarter worth about $171,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.